- Home
- MFIN vs GNLX Comparison
MFIN vs GNLX Comparison
Compare MFIN & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFIN
- GNLX
- Stock Information
- Founded
- MFIN 1995
- GNLX 2001
- Country
- MFIN United States
- GNLX United States
- Employees
- MFIN N/A
- GNLX N/A
- Industry
- MFIN Finance: Consumer Services
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- MFIN Finance
- GNLX Health Care
- Exchange
- MFIN Nasdaq
- GNLX Nasdaq
- Market Cap
- MFIN 207.3M
- GNLX 184.4M
- IPO Year
- MFIN 1996
- GNLX 2023
- Fundamental
- Price
- MFIN $9.17
- GNLX $2.96
- Analyst Decision
- MFIN
- GNLX Strong Buy
- Analyst Count
- MFIN 0
- GNLX 4
- Target Price
- MFIN N/A
- GNLX $17.75
- AVG Volume (30 Days)
- MFIN 44.4K
- GNLX 138.9K
- Earning Date
- MFIN 04-30-2025
- GNLX 05-06-2025
- Dividend Yield
- MFIN 4.80%
- GNLX N/A
- EPS Growth
- MFIN N/A
- GNLX N/A
- EPS
- MFIN 1.60
- GNLX N/A
- Revenue
- MFIN $316,751,000.00
- GNLX N/A
- Revenue This Year
- MFIN N/A
- GNLX N/A
- Revenue Next Year
- MFIN $6.21
- GNLX N/A
- P/E Ratio
- MFIN $5.73
- GNLX N/A
- Revenue Growth
- MFIN 13.93
- GNLX N/A
- 52 Week Low
- MFIN $6.48
- GNLX $1.60
- 52 Week High
- MFIN $10.50
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- MFIN 60.44
- GNLX 54.28
- Support Level
- MFIN $9.00
- GNLX $2.26
- Resistance Level
- MFIN $9.34
- GNLX $3.06
- Average True Range (ATR)
- MFIN 0.28
- GNLX 0.31
- MACD
- MFIN 0.04
- GNLX 0.04
- Stochastic Oscillator
- MFIN 79.76
- GNLX 78.42
About MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The five operating segments are, (1) recreation, (2) home improvement, (3) commercial, (4) taxi medallion, and (5) strategic partnership loans. The company generates maximum revenue from the Recreation segment.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.